autologous peripheral blood stem cell transplantation Autologous peripheral blood progenitor cell (PBPC) transplantation is a proven method of bone marrow (BM) rescue following high-dose chemotherapy for treatment of malignancy. However, the period of neutropaenia immediately following the procedure carries a high risk of infection and haemorrhage, which can be life threatening. In addition, slow immune reconstitution is thought to allow for residual disease progression and is associated with reduced overall survival in cancer patients. 1, 2 The administration of haemopoietic growth factors such as granulocyte-colony stimulating factor (G-CSF) has been used to accelerate neutrophil reconstitution in the short term, but may adversely affect haemopoietic function in the long term. 3 To date, the most critical parameter for ensuring both early and late BM engraftment following PBPC transplantation is widely accepted to be the overall number of CD34 þ progenitor cells infused per kilogram of body weight. 4, 5 Despite this, some patients recuperate successfully after receiving only minimal numbers of CD34 þ cells, while 5-35% of patients who receive adequate infusions still experience delayed BM engraftment. 6 This suggests that the replicative capacity of the infused cells may be variable, and if known, could be used prognostically to identify patients who will suffer a slow recovery. One determinant of cellular proliferation potential is telomere length.
Telomeres are a series of 10-15 kbp of tandem repeat (TTAGGG) n sequences located at the ends of human chromosomes. Together with associated proteins, telomeres contribute to chromosome stability by protecting from endto-end fusion, degradation and recombination of doublestranded DNA ends. 7 Each time a somatic cell divides, 50-100 bp of telomeric sequence is lost from the 3 0 lagging strand of the replicated DNA due to incomplete endreplication by DNA polymerase. Thus, it has been well documented that telomere length decreases with age in many types of somatic cells. 8 Once telomeres reach a critical length (known as the Hayflick limit), the cell exits the cell cycle and becomes senescent. 9 This forms the basis for the theory of a 'mitotic clock', where cells are born with a specific allocation of telomeric sequences that essentially determines their replicative lifespan. 10 Numerous studies have shown increased loss of donor cell telomeric repeats as a consequence of BM and PBPC transplantation. [11] [12] [13] This accelerated telomere shortening is estimated to reach the equivalent of up to 40 years of normal ageing in the first year following transplantation. 13 Although there have been many investigations into telomere length dynamics following BM transplantation, none have explored the effect of infused progenitor cell telomere length on short-term haemopoietic recovery. This parameter may be particularly important for cancer treatment, where autologous PBPC transplantation is being used for patients whose advanced age and prior intensive chemotherapy treatment would negatively impact on the length of their haemopoietic progenitor cell telomeres, possibly reducing the replication potential of these cells. 14 The aim of the present study was to determine if BM engraftment time following PBPC transplantation is related to the telomere length of the infused haemopoietic progenitor cells. We have previously shown that the telomere length of CD34 þ haemopoietic stem cells is equivalent to that of the entire PBPC cell population. 15 Therefore, a retrospective analysis was conducted to determine the mean telomere length of PBPC harvests in patients who had received these as autologous transplants for BM rescue following high-dose chemotherapy for malignancy. The relative contribution of telomere length towards BM recovery time (measured in days to reach absolute neutrophil counts (ANC) X0.1 Â 10 9 , X0.5 Â 10 9 , X1.0 Â 10 9 /l and platelet counts X20 Â 10 9 and X50 Â 10 9 /l) was then determined with regard to other variables of patient age, gender, the number of CD34 þ cells infused, and the administration of G-CSF post transplantation.
Patients, materials and methods

Patient population
The study population consisted of 36 Caucasian patients who had undergone harvest and autologous transplant of PBPC at the Haematology Unit of the Newcastle Mater Misericordiae Hospital from 1996 to 2000. Stored PBPC samples for analysis were selected on the basis that the patients were in clinical remission at the time of PBPC harvest, had no evidence of malignancy in BM aspirates examined immediately prior to harvest, and had suffered no major complications during haemopoietic recovery following transplant. The study was approved by the Hunter Area Research Ethics Committee (Ref 00/03/15/ 3.01) and appropriate informed consent was obtained.
PBPC mobilisation and harvest
Mobilisation of PBPCs was induced by treatment with G-CSF alone in seven patients, cytotoxic therapy alone in two patients, and a combination of both in 27 patients. Leukapheresis was commenced when a sustained rise in total leukocyte count 41.0 Â 10 
Autologous PBPC transplantation and haemopoietic engraftment
The day of autologous PBPC reinfusion was designated 'day 0' for the purposes of this study. /l. During the recovery period, 20 patients from the study group received 'complete' treatment with G-CSF, consisting of 5 mg/kg/day Neupogen (Filgrastim; Amgen, North Ryde, Australia) administered from the first day (day 1) following transplantation and continuing until neutrophil engraftment occurred; nine patients received 'incomplete' treatment with G-CSF, where daily administration of Neupogen was started on later days following transplantation (day 2, n ¼ 1; day 3, n ¼ 1; day 5, n ¼ 2; day 6, n ¼ 2; day 8, n ¼ 2; day 10, n ¼ 1) and continued until neutrophil engraftment occurred; and seven patients did not receive any G-CSF during the recovery period.
Measurement of PBPC mean telomere length
The mean telomere length of each PBPC sample was determined using Southern blotting techniques. 13 Briefly, genomic DNA was isolated and digested with restriction enzymes, RsaI and MspI (Amersham Pharmacia Biotech, Uppsala, Sweden), electrophoresed through a 0.6% agarose gel and transferred onto Hybond N þ membrane (Amersham Pharmacia Biotech). A fluorescein-labelled oligonucleotide probe (CCCTAA) 3 was hybridised to the membrane and detected using enhanced chemiluminescent detection (Amersham Pharmacia Biotech). Kodak Digital Science documentation software was used to determine the net intensity at 1 kbp intervals along the length of the telomere smear. The mean telomere length was calculated as S(MW i Â NI i )/ S(NI i ), where MW i is the molecular weight (kbp) at interval i and NI i the net intensity (pixels) at interval i.
8 Assessment of the accuracy of the methodology showed a mean (7s.e.) within-day variation of telomere length of 671% and between-day variation of 972%.
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For each sample, the average of two mean telomere lengths calculated from two separate blots was used for statistical analysis.
Statistical analysis
All data were normalised and statistical analysis was performed using the Statistica (Statsoft, Tulsa, OK, USA) software package. Differences between means in groups of patients who did or did not receive G-CSF from day 1 post transplantation were evaluated by Wilcoxon rank-sum test. Pearson's correlation coefficients were calculated to examine linear relationships between continuous variables, and mean values of telomere length for different groups were compared by ANCOVA to adjust for age. Multivariate analysis was performed using linear regression where initial models included the independent variables of age, gender, telomere length, and number of CD34 þ cells reinfused, and final models were obtained by stepwise regression. Tests were considered significant when Po0.05.
Results
Patient characteristics and haemopoietic engraftment
General and clinical characteristics as well as PBPC mean telomere length and haemopoietic engraftment data for the patient cohort are presented in Table 1 . The study population consisted of 19 males and 17 females with a mean age of 46.6711.1 years. All had undergone autologous PBPC transplantation as part of treatment for various malignancies, the majority of which were NHL (n ¼ 25). Most patients were in complete remission at the time of PBPC harvest (n ¼ 26). Average telomere lengths of the PBPC collections were found to vary widely within the study group, ranging from 6.01 to 13.7 kbp, with a mean of 9.472.3 kbp. Patients whose mobilisation regimen included chemotherapy in combination with G-CSF (n ¼ 27) tended to have PBPC harvests with shorter telomeres (9.372.1 kbp) than those who had received only G-CSF alone (10.773.0 kbp). However, this was not statistically significant even after adjustment for age (P ¼ 0.16). There was also no significant difference in mean telomere length between patients in partial (n ¼ 10) as opposed to complete (n ¼ 26) remission (9. 
Neutrophil recovery
Patients who had received G-CSF from day 1 post transplantation (n ¼ 20) showed shorter median times to recover neutrophil levels of 0.1, 0.5 and 1.0 Â 10 9 cells/l compared with the seven patients who received no G-CSF during the recovery period (8 vs 11, 9 vs 13 and 10 vs 13 days, respectively). These differences were statistically Table 1 Summary of patient characteristics, autologous PBPC transplantation and haemopoietic engraftment data þ cells/kg reinfused, average telomere length and time to platelet recovery, were not significantly different between the two groups. The nine patients who received incomplete treatment with G-CSF, as described in the Methods, were omitted from this analysis.
The relationship between telomere length and neutrophil recovery times was then analysed separately for each group of patients who had received either 'complete' or 'no' post transplantation administration of G-CSF. Correlation analysis (Figure 1 ) indicated that telomere length was inversely proportional to neutrophil recovery in patients who received no G-CSF during the recovery period (n ¼ 7; r ¼ À0.88 for ANC X0.1 Â 10 9 cells/l, r ¼ À0.81 for ANC X0.5 Â 10 9 cells/l, r ¼ À0.77 for ANC X1.0 Â 10 9 cells/l), with all coefficients statistically significant (Po0.05). However, there was no significant correlation between telomere length and neutrophil recovery to 0.1, 0.5 or 1.0 Â 10 9 cells/l in patients who had received complete G-CSF treatment (n ¼ 20; r ¼ 0.00, 0.16 and 0.04, respectively). The relative importance of telomere length for each neutrophil recovery level in the absence of G-CSF (days to ANC X0.1, 0.5 and 1.0 Â 10 9 cell/l, respectively) was further investigated by stepwise multivariate analysis including other important variables of age, gender and number of CD34 þ cells reinfused. Table 2 shows that telomere length was statistically significantly related to each level of neutrophil recovery. Telomere length alone explained 77% of the variability in the number of days to reach ANC X0.1 Â 10 9 cells/l (P ¼ 0.009). Telomere length together with gender predicted 87% of the variability to ANC X0.5 Â 10 9 cells/l (P ¼ 0.012), with telomere length being the most statistically significant variable (P ¼ 0.016). Finally, recovery to ANC X1.0 Â 10 9 cells/l was also highly dependent on telomere length (P ¼ 0.014), and 81% of the variability in this level of recovery was explained by the two variables of telomere length and age. 
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Platelet recovery
We found no difference between platelet recovery times for patients who received complete or no G-CSF treatment post transplantation (refer to Table 1 ). Therefore, patients who received complete, incomplete and no G-CSF treatment post transplantation were all included in the analysis of platelet recovery. In a simple regression analysis of all evaluable patients (n ¼ 35), platelet recovery was not correlated with telomere length (R 2 ¼ 0.008, P ¼ 0.61 for days to reach X20 Â 10 9 platelets/l; R 2 ¼ 0.00, P ¼ 1.0 for X50 Â 10 9 platelets/l). However, females in our cohort had an average telomere length that was 1.3 kbp longer than that of the males in a trend towards significance even after adjustment for the slight gender difference in age (P ¼ 0.09; Table 3 ). Females also had statistically significantly faster platelet recoveries than males (11.0672.86 vs 14.874.26 days to X20 Â 10 9 platelets/l, P ¼ 0.003; and 13.873.0 vs 20.278.8 days to X50 Â 10 9 platelets/l, P ¼ 0.007). As a result, gender-specific models were evaluated by multivariate analysis. However, it was found that none of the variables of telomere length, age, or the number of CD34 þ cells infused at the time of transplantation could account for any significant variability in platelet recovery to X20 Â 10 9 /l (F (3, 15) 
Discussion
The overall number of CD34 þ cells infused per kilogram of body weight has long been recognised as the most critical parameter for ensuring successful haemopoietic engraftment following stem cell transplantation. 4, 5 A minimum number of 2 Â 10 6 CD34 þ cells per kilogram is generally agreed to be sufficient for both short-and long-term recovery of haemopoietic function. 16 However, for the 35/ 36 patients in our cohort who received at least this amount of reinfused progenitor cells, neutrophil recovery was still found to vary from 6 to 13 days, suggesting that other factors must also affect BM reconstitution. One of these is the administration of G-CSF post transplantation, and our results are in keeping with the widely accepted practice of using this growth factor to accelerate early neutrophil recovery in these patients. 6, [17] [18] [19] Our findings demonstrated that early BM engraftment time in the absence of G-CSF was significantly and inversely correlated with the telomere length of the infused progenitor cells. This discovery supports previous evidence of the importance of the replication potential of CD34 þ cells in their ability to repopulate the BM. Early studies in mice demonstrated replicative senescence of haemopoietic stem cells after serial BM transplantation. 20 Later repetition of these experiments has confirmed that even murine stem cells, which have exceptionally long telomeres, experience substantial telomere shortening during the increased replicative demand that occurs during BM transplantation. 21 Furthermore, the extent of such reduced telomere length in both mice and human BM recipients has been shown in some studies to be inversely correlated with the number of cells infused. 12, 21, 22 Taken together, these findings suggest that both the number and inherent proliferation potential of CD34 þ cells are important for BM engraftment following transplantation.
It is conceivable that the effects of telomere deficiency on neutrophil recovery time may be overcome by post transplantation administration of G-CSF. Such a phenomenon has been documented in a case report where G-CSF was used to successfully treat neutropaenia in a young recipient of an allogenic BM transplant from an elderly donor, where late graft failure was believed to be due to critically short haemopoietic progenitor cell telomere length. 23 These authors postulated that aplasia due to telomere shortening should not be responsive to growth factors. However, ex vivo studies have shown that the enzyme responsible for adding telomeric units to chromosomal ends, telomerase, becomes upregulated in CD34 þ cells when cultured in the presence of G-CSF and other cytokines. 24 These data have been supported by recent investigations in vivo, which have shown that telomerase activity greatly increases in haemopoietic CD34
þ cells in just 48 h after clinical administration of G-CSF. 25 Furthermore, in patients undergoing chemotherapy treatment for NHL, concurrent G-CSF administration has been shown to protect against telomere loss in CD34 þ cells. 25 Thus, the clinical administration of G-CSF may increase the proliferation potential of progenitor cells by upregulating telomerase activity and preserving telomere length. This may also be advantageous during the PBPC mobilisation process in order to ensure that the harvested cells maintain sufficient telomere lengths for future engraftment. In our patient cohort, those who were mobilised with G-CSF alone had slightly longer PBPC telomeres than those who received treatment with G-CSF in combination with chemotherapy. The comparative telomere lengths of PBPC in patients who are mobilised with chemotherapy alone remains to be determined.
Although the main effect of G-CSF is to accelerate granulocyte maturation, it also triggers a cascade of cytokine release that would undoubtedly lead to numerous physiological effects, most of which remain unknown. Most notably, G-CSF has been shown to prevent apoptosis of Table 3 Gender differences in telomere length and platelet recovery myelodysplastic haemopoietic precursors by inhibiting cytochrome c release from the mitochondria. 26 In some cells, telomere shortening also induces apoptosis. 27 It is tempting to speculate that G-CSF administration post transplantation may in fact artificially inhibit programmed cell death of the subset of haemopoietic precursors with critically shortened telomeres; cells that would normally be destined for apoptosis. Although this would result in immediate improvement in neutrophil numbers, it would only delay the inevitable failure of the graft in the long term after growth factor removal. This may explain recent findings that suggest G-CSF treatment following stem cell transplantation is associated with long-term impairment of haemopoietic function. 3 To our knowledge, there has only been one other study investigating the influence of telomere length on BM engraftment, and this analysed long-term recovery rates, as opposed to the short-term parameters examined here.
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In their report on 14 autologous transplant patients, Akiyama and co-workers found no correlation between telomere length and PB ANC or platelet counts recorded 1 year post transplant. It was not clear if these patients had received G-CSF during recovery, in which case the results would be consistent with the present study. Alternatively, the discrepant findings may simply reflect the fact that telomere length is an important predictor of haemopoietic recovery in the short term, but other factors become more significant in determining the long-term repopulating ability of the infused stem cells. Akiyama's group commented that there appeared to be a critical telomere length of 7 kbp required for long-term haemopoiesis. It would be interesting to determine if this were also the case for short-term recovery; however, none of the patients in our no-G-CSF group had a telomere length shorter than 7 kbp.
In our patient cohort, platelet recovery was more significantly influenced by gender than by any other independent variable. This is not supported by other studies which have consistently shown that the number of CD34 þ cells infused is the most important predictor of platelet recovery following transplant. [17] [18] [19] Our findings are most probably a reflection of this fact, as the females in this study were infused with an overall higher number of CD34 þ cells than the males, although this did not achieve statistical significance. Overall, the females of our mature cohort were also found to have longer PBPC telomeres than the males, consistent with reports by others. 28 Also, PBPC telomere length was not correlated with age in our study population, confirming that telomere length can be vastly different among individuals of a similar age. 29 In addition, it is not clear if the 'Hayflick limit' is set at the same telomere length for all cell types or individuals, as recent evidence suggests that replicative senescence is dependent on the protective status of the telomere rather than the absolute length. 30 Clearly, more work is needed to determine the implications of telomere dynamics on replicative senescence in haemopoietic progenitor cells.
There are several limitations to this study that will benefit from further investigations. A larger number of patients would allow the investigation of effects of different premobilisation chemotherapy on telomere length of harvested cells. In addition, different leukocyte subpopulations may display subtle differences in telomere length due to disease and treatment regimes. With increasing concern over the use of recombinant growth factors, there is also a rising need to be able to better determine the individual requirement for such supplements. Thus, larger studies on the effect of telomere length on both long-and short-term haemopoiesis are warranted.
